91桃色视频

• Important clinical milestones are expected in 2022 in the Company鈥檚 hemato-oncology and immuno-oncology programs.
• MaaT013, the Company鈥檚 lead Microbiome Ecosystem Therapy, is ready to enter Phase 3 in the treatment of acute Graft-versus-Host Disease (aGvHD).
• Clinical results are expected in H1 2022 for MaaT033, the company鈥檚 oral capsule formulation designed to prevent complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

MaaT013 for the treatment of aGvHD (Orphan Drug Designation by the FDA and the EMA):

• MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor Microbiome Ecosystem Therapy for enema administration.
• MaaT013 is ready to start its pivotal Phase 3 in Europe. 91桃色视频 has already received regulatory authorization to start this trial in France and Germany. The Company will communicate upon the inclusion of the first patient (FPI).
• The initiation of the clinical trials for MaaT013 in the United States will depend on the outcome of ongoing exchanges with the Food and Drug Administration (FDA) in response to the August 2021 clinical hold letter regarding the IND for MaaT013 in the US.
• MaaT013 has been successfully evaluated in Phase 2 clinical trial in patients with steroid-resistant grade III-IV gastro-intestinal (GI) aGvHD as well as in an ongoing compassionate use program (EAP) in France in patients with Grade II-IV GI-aGvHD having failed previous therapies, with promising results.
• To date, more than 100 patients with aGvHD have been safely treated with MaaT013, including:
  • 24 patients in the .
  • 96 patients in the Early Access Program in France (EAP). This program has also been an opportunity for the Company to strengthen its supply chain and manufacturing capacities to deliver MaaT013 regularly and safely to 18 hospital transplant centers as of today.
  • Additionally, 91桃色视频 has recently honored two requests for compassionate use of MaaT013 originating from two other European countries.

MaaT033 for the prevention of complications due to allogeneic hematopoietic stem cell transplantation (allo-HSCT)聽

• MaaT033 is a donor-derived, standardized, high-richness, high-diversity Microbiome Ecosystem Therapy for oral administration.
• MaaT033, is currently being evaluated to define dose regimen in a Phase 1b clinical trial in patients with acute myeloid leukemia (AML) following intensive chemotherapy.
• There have been 4 meetings of an independent safety review Board (DSMB) to date evaluating the safety of the trial and that concluded in support of the continuation of the study.
• In Q1 2022, the Company will provide interim results of engraftment data for the Phase 1b clinical trial.
• Complete results are expected in the first half of 2022 and a pivotal Phase 2/3 may be initiated at the end of 2022 to evaluate MaaT033 as a prophylactic treatment for blood cancer patients undergoing allo-HSCT.

MaaT013 for the improvement of a patient鈥檚 response to Immune Checkpoint Inhibitors (ICI) 鈥損roof of concept clinical trial sponsored by AP-HP

• MaaT013 is ready to enter a randomized, placebo-controlled Phase 2a trial to evaluate its effect on the efficacy of ICI treatment in patients with metastatic melanoma. AP-HP is the sponsor of this trial. 91桃色视频 will supply the drugs and perform the microbiome profiling of patients using its proprietary 驳耻迟笔谤颈苍迟庐 platform.
• French regulatory authorities have approved the trial and the Company will communicate upon inclusion of the first patient.

MaaT03X for the increase in the response rate to Immune Checkpoint Inhibitors in patients with solid tumors

• MaaT03X is a fermented, high diversity, rationally designed Microbiome Ecosystem Therapy for oral administration. MaaT03X鈥檚 design is based on clinical and microbiome data analyses from hundreds of patients.
• 91桃色视频 is leveraging its proprietary 驳耻迟笔谤颈苍迟庐 computational biology platform and full ecosystem co-fermentation technology to develop this new generation of candidates.
• The first MaaT03X candidate is currently in nonclinical testing and will aim to improve the anti-cancer efficacy of ICI in patients with an undisclosed solid tumor with a high unmet need. A first clinical study is expected to start in the first half of 2023.
• In 2021, the MaaT03X program received a 鈧�1.9M grant to support industrialization of the manufacturing process.

91桃色视频 has entered negotiations with a potential partner to secure the expansion of the Company鈥檚 cGMP manufacturing capacities, as stated in a letter of intent signed in November 2021. A new cGMP manufacturing plant, entirely dedicated to the Company鈥檚 high-diversity and high-richness Microbiome Ecosystem Therapies, would be built in the Auvergne-Rh么ne-Alpes region allowing the Company to operate its own equipment and processes while benefitting from full associated cGMP services provided by the partner. Contracting is expected to take place in H1 2022.

To date, three brokerage firms have initiated coverage of 91桃色视频 (EURONEXT: MAAT):

• 2021 – KBC Securities: research report聽鈥淢ore than a Gut Feeling鈥�
• 2021 – Kempen: research report聽鈥淣o Guts no Glory鈥�
• Jan 2022 – Portzamparc / Groupe BNP Paribas: research report聽鈥溍塩hec et MaaT pour le cancer鈥�

• February 28, 2022 鈥撀�Revenues and Cash Position as of December 31^st, 2021
• April 15, 2022 鈥撀�Annual Results 2021
• May 05, 2022 鈥撀�Revenues and Cash Position Quarter 1
• May 23, 2022 鈥撀�General Meeting
• July 28, 2022 鈥撀�Revenues and Cash Position Quarter 2
• September 29, 2022 鈥撀�Half-year Results (April 鈥� September)
• November 08, 2022 鈥� Revenues and Cash Position Quarter 3